Cutaneous Oncology News

Lynn M. Schuchter, MD, FASCO, has been elected ASCO president for the 2023-2024 term.

Patients who underwent complex reconstruction following Mohs micrographic surgery were more satisfied with their appearance and scars in the long-term, according to a presentation.

Patients with skin of color are more likely to have larger Mohs micrographic surgery defect sizes than white patients, highlighting disparities in non-melanoma skin cancer, according to a presentation.

OCT-guided and temperature-controlled hyperthermic treatment could be a safe, noninvasive alternative to surgical tumor removal in superficial basal cell carcinoma, according to a presentation of preliminary data.

The FDA approved pembrolizumab as adjuvant therapy for adults and children aged 12 years or older with stage IIB or IIC melanoma after complete resection.

Combination therapy with photodynamic treatment and aminolevulinic acid 20% solution has shown strong outcomes with minimal adverse events in actinic keratoses, according to results of a meta-analysis.

Patient-led surveillance following melanoma surgery was safe and feasible, according to a pilot study.

The FDA granted fast track designation to BNT111 for the treatment of advanced melanoma.

Individuals with skin of color are still underrepresented in clinical trials of sunscreens, according to a study.

Patients with BRAF V600 mutation-positive metastatic melanoma who received an immune checkpoint inhibitor combination followed by targeted therapy survived longer than those who received the reverse sequence, according to study findings.